Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Safety of a Vaccine Against Cervical Cancer in Healthy Korean Females

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Female subjects aged between and including, 10 to 25 years at the time of the first vaccination.~* Subjects who the investigator believes that they or their parents/guardians can and will comply with the requirements of the protocol (e.g., completion of the diary cards, return for vaccination visits etc) should be enrolled in the PMS.~* Written informed consent obtained from the subject or the subjects' parent/ guardian.~* Subjects of childbearing potential must not be pregnant. Absence of pregnancy should be verified (e.g. urine pregnancy test) as per the investigator's clinical judgement.~* Subjects with no contraindication according to the local approved prescribing information.~* No previous administration of an HPV vaccine other than Cervarix®.~* No previous administration of more than two doses of Cervarix®.~* No planned administration of an HPV vaccine other than Cervarix® during the PMS

- Gender: FEMALE
- Minimum Age: 10 Years
- Maximum Age: 25 Years
- Healthy Volunteers: t

Study Arms:
- Cervarix Group (Type: None): Subjects received 3 doses of the Cervarix vaccine. The vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm according to a 0,1, 6 month vaccination schedule. According to the prescribing information, if flexibility in the vaccination schedule is necessary, the second dose can be administered between 1 month and 2.5 months after the first dose.

Based on this trial design, predict the completion outcome and termination type (if applicable).